Vimarsana
Biggest News Aggregation in the World

Page 3 - Yelin Jun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yelin Jun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yelin Jun Today - Breaking & Trending Today

GC Biopharma Signs Power Purchase Agreement with SK E&S - Thailand Business News - Vimarsana News

GC Biopharma Signs Power Purchase Agreement with SK E&S - Thailand Business News

YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced on today that it has signed Power Purchase Agreement (PPA) with SK

GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS) - Vimarsana News

GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)

/PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, announced on Sep. 5th that it has adopted the Lab Information Management System for the...

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics - Vimarsana News

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

/PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,...

Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements. - Vimarsana News

Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.

/PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing...

U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid) - Vimarsana News

U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

/PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S....